CORI Corium International, Inc. gains 16% Jan 31, 2018

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, that has completed Phase III clinical trial to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trial for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trial for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Ropinirole TDS that is in preclinical stage for the treatment of Parkinson's disease; MicroCor Zolmitriptan that is in preclinical stage for treatment of migraine; and generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements primarily with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Endo Pharmaceuticals, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California. http://www.priceseries.com/trade/CORI-Corium-International-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2018011120180131.html